human
rhinovirus
hrv
one
major
caus
common
cold
human
also
associ
acut
asthma
bronchial
ill
heatshock
protein
molecular
chaperon
import
host
factor
replic
singlestrand
rna
virus
current
studi
examin
effect
inhibitor
pochonin
vitro
vivo
use
murin
model
human
rhinoviru
type
infect
data
suggest
inhibit
significantli
reduc
inflammatori
cytokin
product
lung
damag
caus
infect
viral
titer
significantli
lower
lung
hela
cell
upon
treatment
pochonin
infiltr
innat
immun
cell
includ
granulocyt
monocyt
also
reduc
bronchoalveolar
lavag
bal
pochonin
treatment
infect
histolog
analysi
lung
respiratori
tract
show
pochonin
protect
mice
infect
collect
result
suggest
inhibitor
pochonin
could
attract
antivir
therapeut
treat
hrv
infect
origin
articl
human
rhinovirus
hrv
posit
singlestrand
rna
virus
belong
famili
piconavirida
hrv
infect
human
usual
caus
common
cold
mild
ill
sometim
associ
asthma
exacerb
viral
upper
respiratori
tract
infect
bartlett
et
al
hrv
divid
three
distinct
speci
includ
type
type
b
type
c
immunolog
noncross
reactiv
hrv
serotyp
park
et
al
among
hrv
serotyp
major
account
use
human
intercellular
adhes
cellular
receptor
bind
mous
wherea
remain
minor
serotyp
includ
use
member
lowdens
lipoprotein
receptor
famili
bind
mous
counterpart
bartlett
et
al
thu
thought
suitabl
model
murin
infect
despit
show
highest
incid
occasion
complic
chronic
bronchiti
well
reactiv
airway
diseas
exacerb
approv
medic
treatment
rhinoviru
infect
mani
effort
made
produc
vaccin
prevent
rhinoviru
infect
difficult
produc
appropri
one
exist
immunolog
noncrossreact
rhinoviru
serotyp
ledford
et
al
therefor
studi
concentr
develop
effect
antivir
agent
treat
rhinoviru
infect
underway
alnakib
tyrrel
kda
heat
shock
protein
highli
abund
essenti
evolutionarili
conserv
molecular
chaperon
center
larg
proteinfold
network
geller
et
al
two
cytoplasm
isoform
mammal
induc
isoform
wherea
express
constitut
function
regul
cohort
cochaperon
modul
atpas
cycl
enabl
acquir
select
client
protein
provid
link
chaperon
system
includ
proteasom
degrad
system
protein
degrad
geller
et
al
inhibitor
known
broadspectrum
anticanc
effect
via
block
divers
pathway
cancer
cell
also
inhibit
growth
surviv
cancer
stem
cell
li
et
al
addit
recent
studi
shown
practic
requir
viral
protein
homeostasi
critic
viral
replic
fold
assembl
nagi
et
al
shown
play
import
role
replic
variou
virus
includ
dna
rna
virus
positiveand
negativesens
genom
also
doublestrand
rna
virus
suggest
inhibitor
may
broadspectrum
antivir
effect
geller
et
al
regard
sever
inhibitor
studi
develop
antivir
vitro
influenza
sarscov
hcv
hiv
li
et
al
herp
virus
cmv
vzv
sun
et
al
well
picornavirus
includ
polioviru
coxsackieviru
rhinoviru
geller
et
al
inhibitor
attract
antivir
agent
infect
lack
antivir
therapi
urgent
respons
outbreak
novel
viral
diseas
addit
applic
inhibitor
sever
anim
model
infecti
diseas
demonstr
decreas
viral
replic
case
polioviru
hcv
infect
geller
et
al
nakagawa
et
al
experi
emphas
possibl
use
inhibitor
human
therapeut
agent
sever
inhibitor
known
potenti
therapeut
drug
test
preclin
clinic
stage
necker
workman
radicicol
natur
product
report
one
potent
inhibitor
moulin
et
al
select
block
function
atpas
chaperon
function
roe
et
al
zhou
et
al
despit
potent
activ
radicicol
labil
moieti
rapidli
inactiv
vivo
lead
poor
efficaci
practic
zhou
et
al
pochonin
origin
isol
pochonia
chlamydosporia
radicicol
analog
potenti
inhibitori
abil
moulin
et
al
wang
et
al
choe
et
al
shown
inhibit
replic
herp
simplex
viru
parasit
protozoan
eimeria
tenella
hellwig
et
al
collect
assess
antirhinovir
activ
pochonin
vitro
vivo
found
pochonin
signific
antivir
effect
inhibit
viru
replic
attenu
infectionassoci
lung
inflamm
pochonin
synthes
purifi
recent
report
choe
et
al
ribavirin
sulforhodamin
b
srb
purchas
sigmaaldrich
st
loui
mo
usa
virus
obtain
atcc
american
type
cultur
collect
manassa
va
usa
cultur
hela
cell
human
cervic
cancer
cell
line
song
et
al
hela
cell
maintain
minim
essenti
medium
mem
supplement
fetal
bovin
serum
fb
antibioticantimycot
solut
mem
fb
trypsinedta
antibioticantimycot
solut
purchas
gibco
brl
thermo
fisher
scientif
waltham
usa
wild
type
wt
balbc
mice
purchas
spl
laboratori
anim
compani
koatech
pyeongtaek
korea
mice
use
experi
week
age
mice
intranas
infect
mice
maintain
experiment
facil
kangwon
nation
univers
anim
experi
approv
institut
anim
care
use
committe
kangwon
nation
univers
antivir
activ
assess
srb
method
use
cytopath
effect
cpe
reduct
report
previous
song
et
al
briefli
one
day
prior
infect
hela
cell
cellswel
seed
onto
cultur
plate
bd
bioscienc
san
jose
ca
usa
next
day
medium
replac
medium
contain
mm
fb
dilut
viru
suspens
contain
cell
cultur
infect
dose
viru
appropri
concentr
test
compound
cultur
plate
incub
day
appropri
cpe
achiev
incub
icecold
aceton
min
cell
stain
wv
srb
acet
acid
solut
cell
morpholog
observ
use
axiovert
microscop
axiovert
carl
zeiss
oberkochen
germani
examin
effect
compound
hrvinduc
cpe
bound
srb
solubil
mm
unbuff
trisbas
solut
absorb
read
nm
use
versamax
micropl
reader
molecular
devic
palo
alto
ca
usa
refer
absorb
measur
nm
percentag
cell
viabil
calcul
comparison
base
measur
absorb
addit
cell
morpholog
observ
microscop
magnif
st
ernstleitz
wetzlar
germani
imag
record
perform
elisa
assess
cytokin
chemokin
level
elisa
kit
purchas
ebiosci
elisa
kit
purchas
r
system
bronchoalveolar
lavag
fluid
balf
obtain
describ
previous
seo
et
al
lung
mice
infect
dissect
homogen
level
cytokin
chemokin
lung
homogen
evalu
accord
manufactur
instruct
seo
et
al
absorb
read
nm
use
spectra
max
molecular
devic
total
rna
isol
group
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
revers
transcript
perform
use
rnase
inhibitor
mmlv
rt
buffer
mmlv
revers
transcriptas
oligo
dt
primer
dntp
mixtur
manufactur
promega
madison
wi
usa
quantit
realtim
pcr
perform
use
thunderbird
tm
sybr
qpcr
mix
toyobo
osaka
japan
tm
optic
modul
biorad
hercul
ca
usa
follow
primer
tcc
ggc
ccc
tga
aca
cgg
aca
ccc
aaa
aaa
acc
tgg
atc
gga
acc
tta
gct
tca
gat
tta
cgg
gag
tca
cag
aag
gag
ttg
ccg
agt
aga
tct
caa
cell
bronchial
alveolar
lavag
fluid
balf
lung
collect
stain
follow
antibodi
fluorescein
isothiocyan
conjug
phycoerythrin
conjug
allophycocyanin
conjug
phycoerythrin
conjug
antibodi
use
flow
cytometr
analysi
purchas
bd
bioscienc
data
acquir
fac
vers
system
bd
bioscienc
analyz
use
bd
facsuit
softwar
evalu
effect
pochonin
lung
histolog
mice
dissect
lung
tissu
perform
histolog
analysi
report
previous
ahn
et
al
briefli
lung
tissu
fix
formaldehyd
mask
formalin
dana
korea
incheon
korea
dehydr
grade
concentr
ethanol
wash
xylen
embed
paraffin
paraffin
block
slice
obtain
section
stain
hematoxylin
eosin
h
e
section
observ
pathologist
blind
test
light
microscop
sampl
score
base
extent
edema
hemorrhag
cell
infiltr
analyz
mous
respiratori
tract
excis
mous
respiratori
tract
infect
without
pochonin
treatment
tissu
wash
pb
fix
glutaraldehyd
ted
pella
red
ca
usa
paraformaldehyd
solut
electron
microscopi
scienc
hatfield
pa
usa
cacodyl
buffer
ph
h
fixat
tissu
rins
thrice
cacodyl
buffer
sigmaaldrich
ph
min
sampl
sequenti
immers
ethanol
merck
kenilworth
nj
usa
min
sampl
immers
ethanol
isoamyl
acet
sigmaaldrich
buffer
dri
dri
sampl
observ
use
vpfesem
carl
zeiss
korean
basic
scienc
institut
chuncheon
use
student
ttest
compar
differ
two
group
compar
multipl
group
carri
oneway
anova
follow
newmankeul
test
valu
p
consid
signific
confid
interv
identifi
effect
pochonin
perbiomol
ther
evalu
effect
pochonin
cpe
observ
morpholog
cell
two
day
infect
hela
cell
mock
cell
fig
cell
treat
pochonin
fig
b
pochonin
fig
show
typic
spreadout
shape
normal
morpholog
test
concentr
sign
cytotox
pochonin
observ
fig
b
infect
absenc
pochonin
result
sever
cpe
fig
howev
addit
pochonin
pochonin
infect
hela
cell
inhibit
format
visibl
cpe
fig
thu
cpe
induc
viru
infect
prevent
presenc
pochonin
assess
verifi
vivo
antivir
activ
pochonin
first
determin
patholog
phenotyp
mice
intranas
infect
balbc
mice
intranas
infect
mice
kill
h
day
day
day
viru
inocul
level
proinflammatori
cytokin
includ
viru
titer
lung
assess
mice
infect
produc
significantli
higher
level
supplementari
fig
elev
viru
titer
supplementari
fig
h
day
infect
uninfect
control
mice
level
proinflammatori
cytokin
viru
titer
peak
h
infect
reduc
day
observ
uninfect
mice
report
previous
bartlett
et
al
therefor
decid
monitor
lung
cytokin
level
viru
titer
h
infect
evalu
antivir
activ
pochonin
mice
assess
antivir
activ
pochonin
mice
intraperiton
administ
pochonin
h
prior
h
intranas
infect
perform
placebo
infect
control
mice
administ
vehicl
intraperiton
mice
neg
control
h
infect
sacrif
mice
obtain
lung
sampl
realtim
pcr
analysi
viral
mrna
lung
tissu
reveal
viru
titer
significantli
reduc
pochonin
dtreat
mice
compar
vehicletr
mice
infect
fig
thu
confirm
pochonin
antihrv
activ
vitro
well
vivo
administ
system
via
intraperiton
rout
virusinduc
cytokin
chemokin
secret
alveolar
space
balf
h
infect
viru
infect
increas
secret
leukocyt
activ
innat
immun
respons
induc
inflamm
subaust
et
al
saklatvala
et
al
bartlett
et
al
evalu
effect
pochonin
pulmonari
cytokin
chemokin
induc
hrv
infect
mice
infect
treat
pochonin
twice
h
h
intranas
infect
h
infect
lung
balf
obtain
mice
subject
elisa
measur
cytokin
chemokin
lung
level
significantli
increas
infect
decreas
pochonin
treatment
fig
similarli
level
cxcl
balf
significantli
increas
infect
reduc
pochonin
treatment
howev
level
balf
significantli
alter
infect
fig
data
indic
increas
secret
proinflammatori
cytokin
chemokin
induc
rhinoviru
infect
mitig
pochonin
treatment
identifi
mechan
underli
antiinflammatori
effect
pochonin
rhinoviru
infect
analyz
cellular
infiltr
balf
rhinovirusinfect
mice
pochonin
vehicl
treatment
chang
total
cell
number
lung
balf
observ
treatment
mice
pochonin
supplementari
fig
recent
studi
suggest
myeloidderiv
suppressor
cell
mdsc
expand
cancer
inflamm
infect
might
involv
increas
level
cytokin
chemokin
influenzainduc
pulmonari
inflamm
jeisyscott
et
al
atretkhani
drutskaya
investig
whether
true
rhinoviru
therefor
assess
cellular
infiltr
neutrophil
balf
mice
treat
pochonin
vehicl
fig
alveolar
macrophag
exclud
gate
neutrophil
number
mdsc
balf
show
phenotyp
granulocyt
neutrophil
significantli
higher
rhinovirusinfect
mice
noninfect
mice
moreov
number
cell
decreas
pochonin
treatment
virusinfect
mice
fig
similarli
percentag
mdsc
cell
balf
rhinovirusinfect
mice
higher
control
mice
percentag
granulocyt
neutrophil
balf
mice
reduc
pochonin
treatment
thu
could
confirm
inflammatori
cell
infiltr
lung
significantli
increas
infect
could
significantli
inhibit
administr
pochonin
next
assess
histolog
chang
lung
mice
lung
uninfect
mice
exhibit
typic
normal
pulmonari
tissu
wherea
rhinovirusinfect
mice
demonstr
characterist
inflammatori
lesion
viral
infect
includ
necrot
bronchiol
interstiti
pneumonia
fig
hand
rhinovirusinfect
biomol
ther
mice
treat
pochonin
show
moder
inflamm
reduc
necrosi
inflammatori
cell
infiltr
pulmonari
edema
compar
rhinovirusinfect
mice
without
treatment
score
lung
section
base
extent
edema
hemorrhag
cell
infiltr
fig
mice
show
seriou
hemorrhag
edema
cell
infiltr
compar
control
mice
pochonin
treatment
group
show
reduc
damag
induc
infect
also
observ
chang
airway
cilia
trachea
sem
fig
uninfect
mice
show
abund
cilia
trachea
regular
arrang
intact
septum
howev
trachea
rhinovirusinfect
mice
damag
could
observ
abnorm
cilia
phlegm
contrari
condit
trachea
mice
treat
pochonin
show
amelior
damag
caus
infect
compar
vehicletr
mice
despit
presenc
phlegm
decreas
number
cilia
cilia
pochonin
dtreat
mice
infect
rel
intact
result
suggest
lung
trachea
significantli
damag
rhinoviru
infect
treatment
pochonin
protect
mice
histolog
damag
induc
gener
virusspecif
protein
drawn
attent
treatment
viral
infect
target
howev
focu
antivir
approach
recent
start
move
toward
target
host
factor
essenti
viru
multipl
molecular
chaperon
regul
function
turnov
traffick
sever
protein
includ
signal
regulatori
protein
one
import
host
factor
play
critic
role
viral
life
cycl
inhibitor
report
inhibit
ebola
viru
ebov
replic
caus
degrad
viral
polymeras
smith
et
al
howev
exact
mechan
underli
antiebov
activ
inhibitor
remain
unknown
influenza
viru
infect
requir
viral
genom
replic
associ
subunit
influenza
viru
inhibit
lead
degrad
viral
subunit
besid
inhibitor
reduc
level
assembl
polymeras
complex
result
decreas
viral
rna
level
momos
et
al
recent
studi
show
also
requir
replic
betaherpesvirus
burch
weller
human
cytomegaloviru
infect
model
inhibit
result
degrad
viral
polymeras
reduct
viral
gene
express
via
downregul
pathway
basha
et
al
similarli
flock
hous
viru
influenc
rna
polymeras
stabil
kampmuel
miller
collect
pharmacolog
inhibitor
potenti
broad
spectrum
antivir
agent
addit
univers
activ
divers
viral
infect
inhibitor
show
possibl
overcom
viral
drug
resist
antivir
agent
lead
gener
drugresist
variant
one
major
issu
develop
effect
antivir
therapi
zur
wiesch
et
al
interestingli
inhibitor
report
induc
viral
drug
resist
till
date
therefor
might
particularli
use
antivir
therapi
virus
prone
develop
drug
resist
geller
et
al
inhibitor
also
potent
antiinflammatori
antioxid
action
vascular
tissu
hsu
et
al
inhibitor
shown
extend
surviv
attenu
inflamm
reduc
lung
injuri
murin
sepsi
chatterje
et
al
also
suggest
particip
induc
infect
mice
infect
pfu
intranas
pochonin
treatment
perform
twice
viru
infect
eight
hour
infect
lung
isol
histolog
analysi
perform
describ
materi
method
section
repres
h
e
stain
section
prepar
mice
treat
pochonin
vehicl
b
histolog
score
base
edema
hemorrhag
cell
infiltr
score
given
base
criteria
bar
graph
show
mean
sem
p
p
p
newmankeul
multipl
comparison
test
anova
c
airway
cilia
trachea
isol
mice
observ
sem
trachea
control
pochonin
dtreat
group
sem
lower
magnif
higher
magnif
viral
capsid
protein
fold
assembl
variou
picornavirus
includ
polioviru
rhinoviru
coxsackieviru
render
attract
candid
develop
antivir
vaccin
brenner
wainberg
also
import
subcellular
local
specif
mrna
region
neighbor
mitochondria
could
explain
inhibitori
effect
inhibitor
rna
polymeras
human
rhinovirus
caus
common
cold
human
sometim
acceler
airway
diseas
asthma
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
zaheer
et
al
import
human
respiratori
viru
hrv
nonenvelop
positivesens
singlestrand
rna
viru
involv
upper
respiratori
tract
infect
also
associ
lower
respiratori
tract
diseas
highrisk
popul
exampl
patient
asthma
airway
inflamm
gern
buss
gener
symptom
rhinoviru
mice
sever
howev
present
data
show
level
proinflammatori
cytokin
lung
balf
mice
increas
upon
intranas
infect
report
contribut
pathogenesi
asthma
longterm
infect
liebhart
et
al
jartti
korppi
rincon
irvin
ribavirin
antivir
drug
approv
fda
treatment
rsv
infect
molinosquintana
et
al
also
broadspectrum
antivir
drug
rna
virus
includ
flua
hrv
rsv
shi
et
al
although
ribavirin
known
broadspectrum
antivir
activ
sever
respiratori
virus
limit
due
controversi
efficaci
toxic
kneyber
et
al
inde
ribavirin
show
effici
antivir
activ
infect
experi
ribavirin
show
margin
antivir
activ
hela
cell
infect
data
shown
present
studi
analyz
antivir
activ
pochonin
hrv
infect
although
pochonin
wellknown
inhibitor
moulin
et
al
wang
et
al
choe
et
al
still
uncertain
inhibit
pochonin
directli
associ
antivir
activ
found
treatment
pochonin
lower
level
proinflammatori
cytokin
lung
balf
mice
increas
rhinoviru
infect
furthermor
viru
titer
hrvinfect
mice
treat
pochonin
significantli
decreas
level
similar
mice
also
examin
level
proinflammatori
chemokinescytokin
lung
lysat
lung
rna
concentr
decreas
pochonin
treatment
mice
compar
chemokinescytokin
level
mice
data
suggest
pochonin
may
reduc
inflammatori
damag
rhinovirusinfect
mice
also
found
neutrophil
infiltr
inflammatori
site
reduc
pochonin
treatment
mice
reduct
may
due
mild
viral
infect
inflamm
pochonin
dtreat
group
final
observ
histopatholog
lung
airway
found
pochonin
treatment
amelior
damag
induc
rhinoviru
infect
lung
airway
vitro
pochonin
influenc
cell
viabil
howev
slight
toxic
observ
pochonin
concentr
greater
data
shown
advers
effect
also
observ
mice
treat
pochonin
mgkg
data
shown
dose
pochonin
nontox
mice
also
effect
control
hrv
infect
compar
dose
therefor
necessari
use
appropri
dose
pochonin
ensur
safeti
efficaci
antivir
therapi
collect
block
pochonin
induc
antivir
effect
rhinoviru
infect
reduc
inflammatori
respons
result
treatment
pochonin
enabl
recoveri
viru
infect
mice
